Cargando…

Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have been developed during the last decade that target the vascular endothelial growth factor receptor (VEGFR) are currently being evaluated as treatments for malignant tumors. The increased application of VEGFR-TKIs means that the probability of hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Bo, Ding, Fengxia, Liu, Yang, Xiong, Geng, Lin, Tao, He, Dawei, Zhang, Yuanyuan, Zhang, Deying, Wei, Guanghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341903/ https://www.ncbi.nlm.nih.gov/pubmed/27602778 http://dx.doi.org/10.18632/oncotarget.11813

Ejemplares similares

Technical Note: Consistency of PTW30013 and FC65‐G ion chamber magnetic field correction factors
por: Woodings, S. J., et al.
Publicado: (2019)

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
por: Waliany, Sarah, et al.
Publicado: (2019)

Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhang, Ze-Feng, et al.
Publicado: (2014)

Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
por: Franczyk, Beata, et al.
Publicado: (2023)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

Validating k(Q)=1.0 assumption in TG51 with PTW 30013 farmer chamber for Varian TrueBeam's 2.5 MV imaging beam
por: Grzetic, Shelby, et al.
Publicado: (2018)

Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-β–dependent vascular endothelial cadherin tyrosine phosphorylation
por: Haidari, Mehran, et al.
Publicado: (2014)

Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-β–dependent vascular endothelial cadherin tyrosine phosphorylation
por: Haidari, Mehran, et al.
Publicado: (2014)

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors
por: Wang, Yihua, et al.
Publicado: (2023)

Endothelial receptor tyrosine kinases involved in angiogenesis
Publicado: (1995)

Correction to: Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-β–dependent vascular endothelial cadherin tyrosine phosphorylation
por: Haidari, Mehran, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
por: Xue, Yifei, et al.
Publicado: (2023)

Correction to: Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro
por: Liu, Bo, et al.
Publicado: (2018)

Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro
por: Liu, Bo, et al.
Publicado: (2018)

Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase)
por: Tanaka, Keiji, et al.
Publicado: (1997)

Signaling Network Map of Endothelial TEK Tyrosine Kinase
por: Khan, Aafaque Ahmad, et al.
Publicado: (2014)

Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
por: Dörks, Michael, et al.
Publicado: (2021)

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
por: Hong, Shaodong, et al.
Publicado: (2014)

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
por: van Cruijsen, H., et al.
Publicado: (2007)

Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis
por: Ma, Qing, et al.
Publicado: (2015)

Prostatic utricles without external genital anomalies in children: our experience, literature review, and pooling analysis
por: Liu, Bo, et al.
Publicado: (2019)

The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Takahashi, Shunji, et al.
Publicado: (2023)

Potential Spermatogenesis Recovery with Bone Marrow Mesenchymal Stem Cells in an Azoospermic Rat Model
por: Zhang, Deying, et al.
Publicado: (2014)

Piwil2-transfected human fibroblasts are cancer stem cell-like and genetically unstable
por: Zhang, Deying, et al.
Publicado: (2017)

Urethral reconstruction with autologous urine-derived stem cells seeded in three-dimensional porous small intestinal submucosa in a rabbit model
por: Liu, Yang, et al.
Publicado: (2017)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction
por: Wan, Qian, et al.
Publicado: (2018)

Vascular endothelial ERp72 is involved in the inflammatory response in a rat model of skeletal muscle injury
por: Khalaf, Noureddine Ben, et al.
Publicado: (2021)

Co-expression of Piwil2/Piwil4 in nucleus indicates poor prognosis of hepatocellular carcinoma
por: Zeng, Guangping, et al.
Publicado: (2016)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer: A PRISMA-compliant meta-analysis
por: Lv, Wen-wen, et al.
Publicado: (2019)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Park, Kwonoh, et al.
Publicado: (2014)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease
por: Yin, Zeyu, et al.
Publicado: (2022)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?
por: Bogaard, Harm Jan, et al.
Publicado: (2022)

Regulation of brain endothelial cell physiology by the TAM receptor tyrosine kinase Mer
por: Happonen, Kaisa E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_btuafv2n99isbjig7k3bsq6k9i